This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Influenza (Pandemic)
and you are
between 18 and 49
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian flu vaccine with and without adjuvant 2 in healthy, young adults. The study is divided down into Parts A1, A2 and B. Groups within each Part will receive two doses of the assigned test article on Study Days 0 and 21. There will be a Safety Monitoring Committee assessment following Day 7 for each part, prior to allowing vaccination of subjects in subsequent Parts of the study.

Provided treatments

  • Biological: Monovalent Avian Influenza VLP (H5N1)
  • Biological: Monovalent Avian Influenza VLP (H5N1)
  • Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant
  • Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant
  • Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant
  • Biological: Saline Placebo

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01596725. The sponsor of the trial is Novavax and it is looking for 333 volunteers for the current phase.
Official trial title:
A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant 2.